Karan Bajaj, the visionary founder of edtech unicorn WhiteHat Jr, has raised $16 million (INR 136.4 crore) in seed funding for his new healthtech venture, Complement1. This significant funding round was led by Owl Ventures and Blume Ventures, signaling strong investor confidence in the startup’s mission to revolutionize cancer care through technology and personalized support.
Complement1, emerging from stealth mode, is set to launch the first tech-enabled, clinically validated lifestyle modification platform specifically designed for cancer patients and high-risk individuals. The platform focuses on delivering personalized, daily guidance through one-on-one support from dedicated CoActive Coaches, combining clinical expertise with behavioral science to improve patient outcomes during and beyond cancer treatment.
In a statement, Bajaj highlighted the core mission of Complement1:
“Every oncologist will tell you patients need more support incorporating clinically recommended physical activity, nutrition, and mind-body practices. We’ve cracked the code on daily engagement with personalised, compassionate coaching—helping patients make meaningful, lasting improvements during and beyond treatment.”
The cancer care space has long recognized the importance of complementary therapies, but challenges in patient engagement and adherence have limited their effectiveness. Complement1 aims to bridge this gap by offering a high-touch, tech-driven approach that integrates lifestyle modification into everyday routines. By focusing on physical activity, nutrition, stress management, and holistic wellness, the platform empowers patients to take an active role in their health journey.
Read Also :- Flipkart to Scale Back Quick Commerce Expansion, Focus on Top 8 Cities to Cut Costs
The startup’s approach is grounded in evidence-based practices and supported by a team of healthcare professionals and wellness experts. Its unique combination of clinical validation, AI-enabled personalization, and daily coaching support positions it as a potential game-changer in the $200 billion global oncology care market.
Investors see strong potential in Complement1’s model. Owl Ventures, a leading investor in education and wellness-focused platforms, and Blume Ventures, known for backing early-stage Indian startups, have expressed their belief in the venture’s capacity to bring measurable improvement to cancer care outcomes.
Complement1’s launch comes at a time when there is growing global awareness about the importance of integrated, holistic care in chronic disease management, particularly in oncology. With cancer rates rising and survivorship care becoming increasingly complex, tools that support sustainable behavior change are in high demand.
The funding will be used to scale the platform, enhance technological capabilities, and expand the coaching and clinical team. The startup plans to onboard users in select pilot markets before a broader rollout.
Conclusion:
Karan Bajaj’s transition from edtech to healthtech marks a bold new chapter, driven by purpose and innovation. With Complement1, he aims to fill a critical gap in cancer care, offering hope and personalized support to patients navigating one of life’s most challenging journeys.
Keywords: Karan Bajaj, Complement1, cancer care startup, $16 million funding, Owl Ventures, Blume Ventures, healthtech, lifestyle modification platform, CoActive Coaches, cancer patients, holistic wellness, oncology care, personalized health support.
Leave a comment